441 related articles for article (PubMed ID: 15611321)
1. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.
Iwai Y; Terawaki S; Honjo T
Int Immunol; 2005 Feb; 17(2):133-44. PubMed ID: 15611321
[TBL] [Abstract][Full Text] [Related]
2. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
3. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Iwai Y; Ishida M; Tanaka Y; Okazaki T; Honjo T; Minato N
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12293-7. PubMed ID: 12218188
[TBL] [Abstract][Full Text] [Related]
4. PD-1 inhibits antiviral immunity at the effector phase in the liver.
Iwai Y; Terawaki S; Ikegawa M; Okazaki T; Honjo T
J Exp Med; 2003 Jul; 198(1):39-50. PubMed ID: 12847136
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance.
Wang L; Han R; Hancock WW
Eur J Immunol; 2007 Oct; 37(10):2983-90. PubMed ID: 17899549
[TBL] [Abstract][Full Text] [Related]
8. Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation.
Cullen R; Germanov E; Shimaoka T; Johnston B
J Immunol; 2009 Nov; 183(9):5807-15. PubMed ID: 19812206
[TBL] [Abstract][Full Text] [Related]
9. Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation.
del Rio ML; Penuelas-Rivas G; Dominguez-Perles R; Ramirez P; Parrilla P; Rodriguez-Barbosa JI
Eur J Immunol; 2005 Dec; 35(12):3545-60. PubMed ID: 16285013
[TBL] [Abstract][Full Text] [Related]
10. Recombined CC chemokine ligand 2 into B16 cells induces production of Th2-dominant [correction of dominanted] cytokines and inhibits melanoma metastasis.
Hu K; Xiong J; Ji K; Sun H; Wang J; Liu H
Immunol Lett; 2007 Oct; 113(1):19-28. PubMed ID: 17868906
[TBL] [Abstract][Full Text] [Related]
11. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS
J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
Waeckerle-Men Y; Starke A; Wüthrich RP
Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
[TBL] [Abstract][Full Text] [Related]
13. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
14. CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation.
Meng Q; Yang P; Li B; Zhou H; Huang X; Zhu L; Ren Y; Kijlstra A
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4444-52. PubMed ID: 17003438
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
16. Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein.
Rüttinger D; Li R; Poehlein CH; Haley D; Walker EB; Hu HM; Fox BA
J Immunother; 2008 Jan; 31(1):43-51. PubMed ID: 18157011
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of program death-1 in T cells has mild impact on allograft survival.
Chen L; Hussien Y; Hwang KW; Wang Y; Zhou P; Alegre ML
Transpl Int; 2008 Jan; 21(1):21-9. PubMed ID: 18076633
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
19. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers.
Schilbach K; Schick J; Wehrmann M; Wollny G; Simon P; Schlegel PG; Eyrich M
Transplantation; 2007 Jul; 84(2):214-22. PubMed ID: 17667813
[TBL] [Abstract][Full Text] [Related]
20. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
